Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens.

ABSTRACT: Bladder cancer biomarkers currently approved by the Food and Drug Administration are insufficiently reliable for use in non-invasive clinical diagnosis. Verification/validation of numerous biomarker candidates for BC detection is a crucial bottleneck for novel biomarker development. A multiplexed liquid chromatography multiple-reaction-monitoring mass spectrometry assay of 122 proteins, including 118 up-regulated tissue proteins, two known bladder cancer biomarkers and two housekeeping gene products, was successfully established for protein quantification in clinical urine specimens. Quantification of 122 proteins was performed on a large cohort of urine specimens representing a variety of conditions, including 142 hernia, 126 bladder cancer, 67 hematuria, and 59 urinary tract infection sa

SUBMITTER: Tsai CH 

PROVIDER: S-EPMC6089400 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature